Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension

• Published in: American journal of physiology. Lung cellular and molecular physiology Vol. 327; no. 1; pp. L54 - L64
• Main Authors: Coursen, Julie C., Tuhy, Tijana, Naranjo, Mario, Woods, Adrianne, Hummers, Laura K., Shah, Ami A., Suresh, Karthik, Visovatti, Scott H., Mathai, Stephen C., Hassoun, Paul M., Damico, Rachel L., Simpson, Catherine E.
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.07.2024
• Series: Translational Physiology
• Subjects: Acetylcholinesterase - blood; Aged; Arterial Pressure; Biological Specimen Banks; Early Diagnosis; Fatty Acids - blood; Female; Humans; Linoleic Acid - blood; Lipid Metabolism; Lipidomics; Liquid Chromatography-Mass Spectrometry; Male; Maryland; Michigan; Middle Aged; Predictive Value of Tests; Pulmonary Arterial Hypertension - blood; Pulmonary Arterial Hypertension - diagnosis; Pulmonary Arterial Hypertension - etiology; Pulmonary Artery - physiopathology; Registries; Scleroderma, Systemic - blood; Scleroderma, Systemic - complications; Scleroderma, Systemic - physiopathology; Time Factors; Vascular Resistance; Maryland; Michigan; metabolism; omics; pulmonary arterial hypertension; scleroderma
• DOI: 10.1152/ajplung.00057.2024
• ISSN: 1040-0605; 1522-1504

Abnormal lipid metabolism is evident across time in the development of SSc-PAH, and dysregulated long-chain fatty acid metabolism predicts overt PAH. We sought to investigate differential metabolism in patients with systemic sclerosis (SSc) who develop pulmonary arterial hypertension (PAH) versus those who do not, as a method of identifying potential disease biomarkers. In a nested case-control design, serum metabolites were assayed in SSc subjects who developed right heart catheterization-confirmed PAH ( n = 22) while under surveillance in a longitudinal cohort from Johns Hopkins, then compared with metabolites assayed in matched SSc patients who did not develop PAH ( n = 22). Serum samples were collected at “proximate” (within 12 months) and “distant” (within 1–5 yr) time points relative to PAH diagnosis. Metabolites were identified using liquid chromatography-mass spectroscopy (LC-MS). An LC-MS dataset from SSc subjects with either mildly elevated pulmonary pressures or overt PAH from the University of Michigan was compared. Differentially abundant metabolites were tested as predictors of PAH in two additional validation SSc cohorts. Long-chain fatty acid metabolism (LCFA) consistently differed in SSc-PAH versus SSc without PH. LCFA metabolites discriminated SSc-PAH patients with mildly elevated pressures in the Michigan cohort and predicted SSc-PAH up to 2 yr before clinical diagnosis in the Hopkins cohort. Acylcholines containing LCFA residues and linoleic acid metabolites were most important for discriminating SSc-PAH. Combinations of acylcholines and linoleic acid metabolites provided good discrimination of SSc-PAH across cohorts. Aberrant lipid metabolism is observed throughout the evolution of PAH in SSc. Lipidomic signatures of abnormal LCFA metabolism distinguish SSc-PAH patients from those without PH, including before clinical diagnosis and in mild disease. NEW & NOTEWORTHY Abnormal lipid metabolism is evident across time in the development of SSc-PAH, and dysregulated long-chain fatty acid metabolism predicts overt PAH.